Tadalafil vs sildenafil patient preference in Spanish men with erectile dysfunction: Results from an international multicentric study;Preferencia de Tadalafilo vs sildenafilo en pacientes españoles con disfunción eréctil: Resultados procedentes de un estudio multicéntrico internacional

Actas Urologicas Espanolas

Volumn 30, Issue 1, 2006, Pages 67-79

  Rodriguez Vela L ^a   Lledo Garcia E ^b   Rajmil, O ^c   Mo, D ^d   Cassinello Hervas, A ^e   Casariego, J ^e  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c FUNDACIÓ PUIGVERT   (Spain)

^d ELI LILLY AND COMPANY   (United States)

^e ELI LILLY AND COMPANY   (Spain)

Author keywords

Erectile dysfunction; Phosphodiesterase inhibitors; Preference study; Randomized clinical trial; Sildenafil; Tadalafil

Indexed keywords

EID: 33644994319     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0210-4806(06)73399-x     Document Type: Article

References (27)

1. NIH Consensus Development panel on Impotence. Impotence. JAMA 1993;270:83-90.
2. Leiblum SR. After sildenafil: bridging the gap between pharmacologic treatment and satisfying sexual relationships. J Clin Psychiatry. 2002 Dec;63(12):17-22.
3. Pommerville P. Erectile dysfunction: An overview. Can J Urol 2003;10(suppl. 1):2-6.
4. World Population Projection Program of United Nations (2002 Revision).
5. Martín-Morales A, Sánchez-Cruz JJ, Saenz de Tejada I, Rodríguez-Vela L, Jiménez-Cruz JF, Burgos-Rodríguez R. Prevalence and independent risk factors for erectile dysfunction in Spain: results of the Epidemiologia de la Disfuncion Erectil Masculina Study. J Urol 2001 Aug;166(2):569-574;discussion 574-575.
6. Aytac IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. Br J Urol Int 1999;84:450-456.
7. Wespes E, Amar E, Hatzichristou D, Montorsi F, Pryor J, Vardi Y. European Asociation of Urology. Guidelines on erectyle dysfunction. March 2004.
8. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998;338:1397-1404.
9. Sildenafil Citrate (Viagral) US Package Insert. Nueva York: Pfizer, Inc 2002.
10. Seftel AD. Challenges in oral therapy for erectile dysfunction. J Androl 2002;23:729-736.
11. Ficha Técnica de Tadalafilo, 2004.
12. Brock GB, McMahon CG, Chen KK, Costigan T, Shen W; Watkins V et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002;168(4 Pt 1):1332-1336.
13. Carson CC, Rajfer J, Eardley I, Carrier S, Denne JS, Walker DJ, et al. The efficacy and safety of tadalafil: an update. BJU International 2004;93:1276-1281.
14. Montorsi F, Verheyden B, Jünemann KP, Moncada I, Valiquette L, Denne J. Long-Term Safety and Tolerability of Tadalafil in the Treatment of Erectile Dysfunction. European Urology 2004;45:339-345.
15. Porst H, Padma-Nathan H, Giuliano F, Anglin G, Varanese L, Rosen R. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology. 2003 Jul;62(1):121-125; discussion 125-126.
16. Raymond C. Rosen PhD, Harin Padma-Nathan, MD, Ridwan Shabsigh, MD, Khalil Saikali, PhD, Exec MB, Vish Watkins, MD et al. Determining the Earliest Time within 30 Minutes to Erectogenic Effect after Tadalafil 10 and 20 mg: A Multicenter, Randomized,Double-Blind, Placebo-Controlled, At-Home Study. J Sex Med 2004;1:193-200.
17. Young Y, Feldman RF, Kaufman JK, Averbach SA, Ahuja SA, Purphy AM, et al. Tadalafil 10 and 20 mg Effectively Treat Erectile Dysfunction for up to 36 Hours. J Sex Med 2004;1(suppl1):48,Abstract 061.
18. Chen J, Habjeesh NJ, Greenstein A. Sildenafil versus the vacuum erection device. Patient preference. J urol 2001;166: 1779-1781.
19. Hatzichristou DG, Apostolidis A, Tzortzis V, Ioannides E, Yannakoyorgos K, Kalinderis A. Sildenafil versus intracavernous injection therapy: efficacy and preference in patients on intracaver-nous injection for more than 1 year. J Urol 2000;164:1197-1200.
20. Stroberg P, Murphy A, Costigan T. Switching patients with erectile dysfunction from sildenafile citrate to tadalafil: Results of a European multicenter, open-label study of patient preference. Clinical Therapeutics 2003;25(11): 2724-2737.
21. Govier F, Potempta AJ, Kaufman J, Denne J, Kovalenko P, Ahuja S. A multicenter, randomized, double-blind, crossover study of patient preference for Tadalafil 20 mg or Sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction. Clinical Therapeutics 2003;25(11): 2709-2723.
22. Porst H, Kleingarn M, Arnds S. The two PDE 5 inhibitors sildenafil and tadalafil: results of an independent intraindividual comparative trial [abstract]. Eur Urol Suppl 2004; 3(2):27.
23. Porst H, Arnds S, Kleingarn M. The 3 PDE 5 inhibitors sildenafil, tadalafil and vardenafil: results of an independent intraindividual comparative study [abstract]. Eur Urol Suppl 2004;3(2):104.
24. Von Keith A, Rajfer J, Segal S, Murphy A, Denne J, Costigan T, et al. A multicenter, randomized, double-blind, crossover study to evaluate patient preference between Tadalafil and Sildenafil. European Urology 2004;45:499-509.
25. El Galley R, Rutland H, Talic R, Keane T, Clark H. Long-term efficacy of sildenafil and tachyphylaxis effect. J Urol 2001;166:927-931.
26. Marks LS, Duda C, Dorey FJ, Macairan ML, Santos PB. Treatment of erectile dysfunction with sildenafil. Urology 1999;53:19-24.
27. Orrico KB, Verdiano RM, Wohl LB. Sildenafil Dose Titration Program. Am J Health Syst Pharm 1998;55:2297.